Drug Profile
Research programme: PARP1 inhibitors - Elicio Therapeutics
Alternative Names: ANG-2684; ANG-3038Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Angion Biomedica
- Developer Elicio Therapeutics
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatitis; Stroke
Most Recent Events
- 01 Jun 2023 Angion Biomedica has merged with Elicio Therapeutics to form Elicio Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatitis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA